Table 2.
Dysregulated expression of immune cell-related CD markers in JAK2V617F positive MPNs.
| Markers | Alternative name | Chro. | Function | Type of diseases | Prognosis | Ref. | |
|---|---|---|---|---|---|---|---|
| Decreased expression | Increased expression | ||||||
| CD4C | D4 molecule | 12p13.31 | TH | PMF | - | Maybe associated with decreased immune function | 88 |
| CD8 | CD8 molecule | 2p11.2 | TC | - | |||
| CD5 | CD5molecule | 11q12.2 | B cells | - | PMF | Maybe associated with autoantibody production and autoimmune complications | 88 |
| CD68 | LAMP4 | 17p13.1 | Monocyte | - | PMF | Associated with monocytosis, rapid disease progression and increased predisposition toward CMML | 92, 93 |
| CD177 | NB1 glycoprotein | 19q13.2 | Neutrophil | - | PV, ET, PMF | Maybe associated with bacterial infections | 102, 103, 105 |
| CD4 CD25 | CD4 molecule and IL-2R | 12p13.31 and 10p15.1 | Treg | - | PV, ET, PMF | Maybe associated with poor prognosis via adverse effect on TCD4+ function and immune system suppression | 97, 98 |
| CD39 | ENTPD1 | 10 | Treg | - | PMF | Maybe associated with poor prognosis through severe immune system suppression | 99 |
| CD274 | PDL1 | 9p24.1 | TH | PV, ET | Maybe associated with poor prognosis via immune response failure | 98 | |
chro, chromosome; TH, T helper; TC, T cytotoxic; LAMP4, lysosomal-associated membrane glycoprotein; CMML, chronic myelomonocytic leukemia; IL-2R, interleukin 2 receptor; Treg, regulatory t cells; ENTPD1, ectonucleoside triphosphate diphosphohydrolase 1; PDL1, programmed death cell-1; PV, polycythemia vera; ET, essential thrombocythemia; PMF, primary myelofibrosis.